Home / Jobs / Job Detail

Job Summary

  • Company

    Betta Pharmaceuticals Co., Ltd.​

  • Location

    Zhejiang, China​

  • Job Type

    Full Time

  • Salary Range


  • Number to Recruit


  • Job Reference Code


Senior Pharmaceutical Preclinical R&D Position (Director , Senior Director)

Zhejiang, China

About Company:

Betta Pharmaceuticals Co., Ltd. was established in 2003 and is headquartered in Hangzhou, Zhejiang. It is a national high-tech enterprise established by an experienced team with talented returnees, focusing on research and development (R&D) of innovative drugs, with entire close loops of R&D, manufacturing, and sales. On Nov. 7th,2016, Betta Pharmaceuticals was successfully listed on the Shenzhen Stock Exchange with the stock code: 300558.SZ.

The company has more than 1,900 employees, and has established a senior executive team for innovative drug discovery and commercialization, including dozens of returnees (Ph.D.). The company has set up R&D centers in Beijing, Hangzhou and San Diego, U.S.A.. The company independently developed China's first small molecule anti-cancer drug for EGFR-targeted therapy——Icotinib hydrochloride (trade name: Conmana®), which was approved by the National Medical Products Administration (NMPA) in June 2011. Conmana® has won the Gold Prize of China Patent Award twice as well as the China Industrial Award. It has also been awarded for the National Prize for Progress in Science and Technology, as the first such award granted to a China's chemical pharmaceutical industry and to a Zhejiang enterprise.

In November 2020, Ensartinib hydrochloride capsule (trade name: Ensacove®), which is an innovative drug with independent intellectual property rights, that was jointly developed by Betta and its holding subsidiary Xcovery, was approved by NMPA. It became the first Category 1.1 new drug manufactured domestically in China for the treatment of advanced non-small cell lung cancer (NSCLC) with ALK mutations, which has filled the gap in the same class of drugs in China.

In November 2021, the Bevacizumab injection jointly developed by t Betta and Beijing Mabworks Biotechnology Co., Ltd. was officially approved for marketing, with approved indication is of metastatic colorectal cancer and advanced, metastatic, or recurrent NSCLC. Bevacizumab became the company's first approved biological macromolecular drug, which is also the third marketed drug and the first bevacizumab biosimilar in Zhejiang.

In May 2023, Betta’s fourth marketed drug Befotertinib (trade name: Surmana®) was approved. The third-generation EGFR-TKI is indicated for locally advanced or metastatic NSCLC with T790M mutation due to first-generation EGFR-TKI resistance. The launch of the drug demonstrates Betta’s remarkable R&D capability. The Lancet Respiratory Medicine commented that Befotertinib (Surmana®) as a new candidate in the field of EGFR-mutant advanced NSCLC that can be considered as an alternative strategy for patients in China.

In June 2023, the Category 1 innovative drug Vorolanib was approved by the NMPA used in combination with Everolimus, indicated for the treatment of patients with advanced renal cell carcinoma who progressed after TKI treatment. The drug demonstrates a breakthrough in the field of domestic innovative drugs for renal cell carcinoma.

The company gives full play to its role as the main body of scientific and technological innovation, and continues to increase investment in research and development of new drugs for major diseases that seriously affect human health.Betta’s R&D expenditure increased continuously in the past three years, and has an average of over 40% of the company’s total expenditure. Currently, there are more than 40 innovative drug projects in Betta’s pipeline with 18 in clinical stages, including 4 in phase III clinical trials. The new drug application (NDA) of Ensatinib has been submitted and was granted a priority review by the NMPA. The global multi-center phase III clinical trial of Ensartinib is ongoing and it is expected to be the first lung cancer-targeting innovative drug to be marketed globally by a Chinese pharmaceutical company.

Actively responding the call from the industry, the company also set up a healthcare innovation incubator platform——Betta Dreamworks, to help more scientists achieve their dreams of innovation and entrepreneurship.

Job Profile:

Participate in the formulation of the company's new drug development strategy, lead the new drug R&D center team, complete highly innovative drug development work, address unmet clinical needs, and accelerate the globalization process of the company.

Job Details:




Extensive knowledge and experience in international cutting-edge oncology drug development, solid experience in new drug development from project initiation to successful proof of concept (POC), and multiple projects successfully entering pivotal clinical trials.

Over 15 years of executive leadership and management experience in international pharmaceutical companies: excellent leadership of large research teams

Majored in biology, life sciences, chemistry, or related fields, with a doctoral degree: overseas study experience and abundant scientific research achievements

Strong passion for innovative drug development


National standard insurance package including endowment insurance, medical insurance, unemployment insurance, work-related injury insurance, childbirth insurance, and housing accumulation funds, annual PTO, flexible working hours, incentives, etc.

Apply Now